Follow the Hepion Pharmaceuticals, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €6.8m. The latest transaction was reported on 12 August 2026 (Acquisition). Among the most active insiders: LoPriore Vincent S. The full history is free.
15
Insider Decl.
n/a
Thresholds
€1m
15 ops.
Buy Volume
n/a
n/a
Sell Volume
72Σ signal
Buys €1mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
1,600 shares@ US$5.4049.2% of flowCommon StockSEC:0001104659-23-101391:0
Canonical exit: 14 Dec 2023 (T+90)
15 of 15 declarations
About Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for liver diseases. It primarily concentrates on the research and development of innovative drugs.